InvestWiser

Paxman AB

PAXNasdaq StockholmHealthcareMarket value 1.5 bn SEK
66.40SEK −0.6%
last day · Price as of 18 November 2026

The answer first

Does Paxman beat the market?

No, Paxman has not beaten the market over the last year.

Paxman+7.1%Stockholm (OMXSGI)+17.6%
  • The ranking · Quality, value and trend combined

    Better than 48% of Nordic stocks

    • Quality48
    • Value16
    • Trend89

    No. 64 of 195 in healthcare

Max for seven days

Follow Paxman with Aurora

Aurora lets you know at the next report. No card.

Both with dividends. Figures as of 18 November 2026. General analysis, not personal advice.

Follow your thesis

Follow your thesis on Paxman

From today, at a price of 66.40 SEK. Write why you follow Paxman, and choose what Aurora should tell you about.

What should Aurora follow?

Free, no card. The mission is ready when your account is.

Aurora tells you that something happened. What you do is your choice.

Ask Aurora about Paxman

Your first answer is free, no account needed.

Do you own Paxman, or are you thinking about it?

See it next to the rest of your portfolio, or build your first one with Paxman and a few more. Free, no card.

Past year against the exchange and Super Stock
Paxman+7.1%Stockholm (OMXSGI)+17.6%Super Stock+44.6%
17 November 202518 November 2026
All start at 0 % a year ago, with dividends. Super Stock is our model portfolio: the 20 highest-ranked Nordic stocks on quality, value and trend.

In short

  • Paxman has risen 7.1% over the past year, including dividends.
  • Overall, Paxman ranks better than 48% of Nordic stocks on quality, value and trend.
  • The largest fall over the past three years was 64.0%. The price is 20.8% below its peak now.

What do analysts think of Paxman?

Quality, value and trend

Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.

48

Quality, value and trend together. Better than 48% of Nordic stocks.

No. 64 of 195 in healthcare

Quality48
The company · Fundamentals: the accounts

Medium An average company: the accounts are neither especially strong nor weak.

No. 134 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50

  • Debt to equityBorrowings divided by equity0.03
  • Asset turnoverSales divided by everything the company owns0.75
  • Return on equityProfit divided by equity−1.2%
  • Cash conversionOperating cash flow divided by profit–

The ranking is built on equity ratio, ROA and how steadily profit grows.

Value16
The price · Valuation: the multiples

Low High price: buyers pay a lot today, often because they expect growth.

No. 112 of 197 in healthcareTypical in healthcare: 20Typical in the Nordics: 50

  • P/BPrice divided by equity3.6
  • P/SPrice divided by sales4.1
  • P/EPrice divided by earningsnegative earnings
  • P/CFPrice divided by operating cash flownegative earnings

The ranking is built on P/E, P/B and P/S.

Trend89
The share price · Technical: the price trend

High Tailwind in the share price: it has risen more than most over the last year.

No. 26 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50

  • 3 months+20.7%
  • 6 months+28.7%
  • 9 months+30.2%
  • 12 months+7.1%

The ranking is built on 3, 6 and 12–1 months.

Return and risk

1 month
+0.8%
3 years, per year
+36.7%
5 years, per year
−1.1%
Year to date
+18.1%
Largest fall, 3 years
−64.0%
From a peak to the bottom
From the peak now
−20.8%
How far the price is from the peak
Volatility, 1 year
40.2%
How much the price swings over a year
Beta, 1 year
0.50
How much the price moves when the market moves

Return with dividends reinvested.

The funds that own Paxman

5 funds we follow own Paxman. The share is how much of the fund the stock makes up.

  • Sweden5

From the funds' latest known holdings.

About Paxman

Paxman AB is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 150 employees.

Paxman AB (publ), together with its subsidiaries, provides cryotherapy solutions in the United Kingdom, Europe, North and South America, Oceania, and Asia. The company offers Paxman scalp cooling system, a mechanized form of scalp cooling for the prevention of chemotherapy-induced alopecia. It also engages in the development of a medical cryocompression device for the prevention of chemotherapy-induced peripheral neuropathy. The company was founded in 1996 and is based in Karlshamn, Sweden.

See the full analysis of Paxman.

The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.

Free forever · No card

Other healthcare stocks on Nasdaq Stockholm

Explore the stock market